B. Riley Securities initiates coverage on Elicio Therapeutics with Buy rating
B. Riley Securities analyst Mayank Mamtani initiated coverage on Elicio Therapeutics with a Buy rating and a price target of $27, indicating a positive outlook on the stock.
*this image is generated using AI for illustrative purposes only.
B. Riley Securities analyst Mayank Mamtani has initiated coverage on Elicio Therapeutics with a Buy rating and a price target of $27. The rating reflects a positive outlook on the company's stock performance.
Coverage Details
The initiation of coverage by B. Riley Securities highlights the firm's confidence in Elicio Therapeutics. The Buy rating suggests that the stock is expected to outperform the market.
Price Target
The announced price target of $27 provides a specific valuation benchmark for investors. This target indicates the potential upside from the current trading levels.
| Analyst | Firm | Rating | Price Target |
|---|---|---|---|
| Mayank Mamtani | B. Riley Securities | Buy | $27 |
What specific clinical milestones could drive Elicio Therapeutics' stock toward the $27 price target?
How might competing biotech firms impact Elicio's market position and stock performance?
What are the potential risks or challenges that could prevent Elicio from meeting B. Riley's expectations?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
